
Francesca Sanguedolce

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1177398/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Metabolomic profile of glycolysis and the pentose phosphate pathway identifies the central role of glucose-6-phosphate dehydrogenase in clear cell-renal cell carcinoma. Oncotarget, 2015, 6, 13371-13386.	0.8	138
2	Oral L-Citrulline Supplementation Improves Erection Hardness in Men With Mild Erectile Dysfunction. Urology, 2011, 77, 119-122.	0.5	78
3	Activation of the kynurenine pathway predicts poor outcome in patients with clear cell renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 461.e15-461.e27.	0.8	75
4	Pentraxin 3: A Novel Biomarker for Predicting Progression from Prostatic Inflammation to Prostate Cancer. Cancer Research, 2014, 74, 4230-4238.	0.4	74
5	Role of Runx2 phosphorylation in prostate cancer and association with metastatic disease. Oncogene, 2016, 35, 366-376.	2.6	56
6	Combined Use of Prostate-specific Antigen Density and Magnetic Resonance Imaging for Prostate Biopsy Decision Planning: A Retrospective Multi-institutional Study Using the Prostate Magnetic Resonance Imaging Outcome Database (PROMOD). European Urology Oncology, 2021, 4, 971-979.	2.6	56
7	NY-ESO-1/LAGE-1 coexpression with MAGE-A cancer/testis antigens: A tissue microarray study. International Journal of Cancer, 2005, 115, 960-966.	2.3	54
8	Urine TMPRSS2: ERG Fusion Transcript as a Biomarker for Prostate Cancer: Literature Review. Clinical Genitourinary Cancer, 2016, 14, 117-121.	0.9	52
9	Urinary RKIP/p-RKIP is a potential diagnostic and prognostic marker of clear cell renal cell carcinoma. Oncotarget, 2017, 8, 40412-40424.	0.8	50
10	Increased Expression of the Autocrine Motility Factor is Associated With Poor Prognosis in Patients With Clear Cell–Renal Cell Carcinoma. Medicine (United States), 2015, 94, e2117.	0.4	45
11	Reduced percentage of natural killer cells associated with impaired cytokine network in the secretory endometrium of infertile women with polycystic ovary syndrome. Fertility and Sterility, 2010, 94, 2222-2227.e3.	0.5	41
12	Epigenetic fingerprint in endometrial carcinogenesis: The hypothesis of a uterine field cancerization. Cancer Biology and Therapy, 2011, 12, 447-457.	1.5	37
13	Molecular markers in bladder cancer: Novel research frontiers. Critical Reviews in Clinical Laboratory Sciences, 2015, 52, 242-255.	2.7	32
14	PSA Density Help to Identify Patients With Elevated PSA Due to Prostate Cancer Rather Than Intraprostatic Inflammation: A Prospective Single Center Study. Frontiers in Oncology, 2021, 11, 693684.	1.3	32
15	Radiation-induced intracranial meningiomas: review of six operated cases. Neurosurgical Review, 2005, 28, 104-114.	1.2	31
16	Predictive markers in bladder cancer: Do we have molecular markers ready for clinical use?. Critical Reviews in Clinical Laboratory Sciences, 2014, 51, 291-304.	2.7	31
17	Altered p53 and pRb expression is predictive of response to BCG treatment in T1G3 bladder cancer. Anticancer Research, 2009, 29, 4201-4.	0.5	31
18	Cyclooxygenase Isozymes in Oral Squamous Cell Carcinoma: A Real-Time RT-PCR Study with Clinic Pathological Correlations. International Journal of Immunopathology and Pharmacology, 2007, 20, 317-324.	1.0	30

#	Article	IF	CITATIONS
19	A recurrent epidermoid cyst of the spleen: report of a case and literature review. World Journal of Surgical Oncology, 2016, 14, 98.	0.8	30
20	Prostate cancer detection rates in different biopsy schemes. Which cores for which patients?. World Journal of Urology, 2014, 32, 341-346.	1.2	29
21	Altered expression of HER-2 and the mismatch repair genes MLH1 and MSH2 predicts the outcome of T1 high-grade bladder cancer. Journal of Cancer Research and Clinical Oncology, 2018, 144, 637-644.	1.2	29
22	Development and Internal Validation of Novel Nomograms Based on Benign Prostatic Obstruction-Related Parameters to Predict the Risk of Prostate Cancer at First Prostate Biopsy. Frontiers in Oncology, 2018, 8, 438.	1.3	29
23	Retinoblastoma protein expression predicts response to bacillus Calmette-Guérin immunotherapy in patients with T1G3 bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2010, 28, 285-289.	0.8	28
24	Loss of STK11 expression is an early event in prostate carcinogenesis and predicts therapeutic response to targeted therapy against MAPK/p38. Autophagy, 2015, 11, 2102-2113.	4.3	27
25	An unusual delayed complication of paraffin self-injection for penile girth augmentation. BMC Urology, 2013, 13, 66.	0.6	23
26	Absence of Bladder Outlet Obstruction Is an Independent Risk Factor for Prostate Cancer in Men Undergoing Prostate Biopsy. Medicine (United States), 2016, 95, e2551.	0.4	23
27	Mitochondrial dysfunctions in bladder cancer: Exploring their role as disease markers and potential therapeutic targets. Critical Reviews in Oncology/Hematology, 2017, 117, 67-72.	2.0	23
28	Prognostic and therapeutic role of HER2 expression in micropapillary carcinoma of the bladder (Review). Molecular and Clinical Oncology, 2019, 10, 205-213.	0.4	23
29	Human epidermal growth factor receptor 2 expression is more important than Bacillus Calmette Guerin treatment in predicting the outcome of T1G3 bladder cancer. Oncotarget, 2017, 8, 25433-25441.	0.8	22
30	Central neurocytoma: two case reports and review of the literature. Neurosurgical Review, 2006, 29, 339-347.	1.2	21
31	Bladder Metastases from Breast Cancer: Managing the Unexpected. A Systematic Review. Urologia Internationalis, 2018, 101, 125-131.	0.6	21
32	Gastrointestinal Manifestations in Systemic Mastocytosis: The Need of a Multidisciplinary Approach. Cancers, 2021, 13, 3316.	1.7	21
33	Expression of mitotic kinases phospho-aurora A and aurora B correlates with clinical and pathological parameters in bladder neoplasms. Histology and Histopathology, 2010, 25, 1371-7.	0.5	21
34	Combined perianalâ€intrarectal (PI) lidocaineâ€prilocaine (LP) cream and lidocaineâ€ketorolac gel provide better pain relief than combined PI LP cream and periprostatic nerve block during transrectal prostate biopsy. BJU International, 2012, 109, 1776-1780.	1.3	20
35	Noninfiltrative anesthesia for transrectal prostate biopsy: A randomized prospective study comparing lidocaine-prilocaine cream and lidocaine-ketorolac gel. Urologic Oncology: Seminars and Original Investigations, 2013, 31, 68-73.	0.8	20
36	The Tumor Entity Denominated "clear cell-papillary renal cell carcinoma―According to the WHO 2016 new Classification, have the Clinical Characters of a Renal Cell Adenoma as does Harbor a Benign Outcome. Pathology and Oncology Research, 2018, 24, 447-456.	0.9	20

#	Article	IF	CITATIONS
37	What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 1: Focus on Immunohistochemical Results with Discussion of Pre-Analytical and Interpretation Variables. Cells, 2021, 10, 3166.	1.8	20
38	EBV-Driven Lymphoproliferative Disorders and Lymphomas of the Gastrointestinal Tract: A Spectrum of Entities with a Common Denominator (Part 1). Cancers, 2021, 13, 4578.	1.7	18
39	Prospective Validation of Pentraxin-3 as a Novel Serum Biomarker to Predict the Risk of Prostate Cancer in Patients Scheduled for Prostate Biopsy. Cancers, 2021, 13, 1611.	1.7	16
40	Indolent T-Cell Lymphoproliferative Disorders of the Gastrointestinal Tract (iTLPD-GI): A Review. Cancers, 2021, 13, 2790.	1.7	16
41	What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 3: PD-L1, Intracellular Signaling Pathways and Tumor Microenvironment. International Journal of Molecular Sciences, 2021, 22, 12330.	1.8	16
42	Human Epidermal Growth Factor Receptor 2 in Non-Muscle Invasive Bladder Cancer: Issues in AssessmentÂMethods and Its Role as Prognostic/Predictive Marker and Putative Therapeutic Target: A Comprehensive Review. Urologia Internationalis, 2019, 102, 249-261.	0.6	15
43	Morphological and Immunohistochemical Biomarkers in Distinguishing Prostate Carcinoma and Urothelial Carcinoma: A Comprehensive Review. International Journal of Surgical Pathology, 2019, 27, 120-133.	0.4	15
44	Modulation of complement activation by pentraxin-3 in prostate cancer. Scientific Reports, 2020, 10, 18400.	1.6	15
45	Mitochondrial Caseinolytic Protease P: A Possible Novel Prognostic Marker and Therapeutic Target in Cancer. International Journal of Molecular Sciences, 2021, 22, 6228.	1.8	15
46	Asymptomatic Bladder Metastasis from Breast Cancer. Case Reports in Urology, 2014, 2014, 1-3.	0.1	14
47	Bladder Metastases from Lung Cancer: Clinical and Pathological Implications: A Systematic Review. Oncology, 2017, 92, 125-134.	0.9	14
48	EBV-Driven Lymphoproliferative Disorders and Lymphomas of the Gastrointestinal Tract: A Spectrum of Entities with a Common Denominator (Part 2). Cancers, 2021, 13, 4527.	1.7	14
49	Surgicel® granuloma mimicking ovarian cancer: A case report. Oncology Letters, 2016, 12, 1083-1084.	0.8	13
50	Bioptic intraprostatic chronic inflammation predicts adverse pathology at radical prostatectomy in patients with low-grade prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 793.e19-793.e25.	0.8	13
51	What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review (Part 6): Correlation of PD-L1 Expression with the Status of Mismatch Repair System, BRCA, PTEN, and Other Genes. Biomedicines, 2022, 10, 236.	1.4	13
52	Post-void residual urinary volume is an independent predictor of biopsy results in men at risk for prostate cancer. Anticancer Research, 2015, 35, 2175-82.	0.5	13
53	Magnetic resonance imaging of penile paraffinoma: case report. BMC Medical Imaging, 2014, 14, 39.	1.4	12
54	Bladder metastasis from lung adenocarcinoma: a difficult differential diagnosis with primary bladder adenocarcinoma. World Journal of Surgical Oncology, 2014, 12, 90.	0.8	10

#	Article	IF	CITATIONS
55	Testicular metastasis as the first clinical manifestation of pancreatic adenocarcinoma: a case report. Journal of Medical Case Reports, 2015, 9, 139.	0.4	10
56	Cathepsin K Expression in Castration-Resistant Prostate Carcinoma: A Therapeutical Target for Patients at Risk for Bone Metastases. International Journal of Biological Markers, 2017, 32, 243-247.	0.7	10
57	What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 4: Experimental Treatments in Pre-Clinical Studies (Cell Lines and Mouse Models). International Journal of Molecular Sciences, 2021, 22, 12297.	1.8	10
58	Abdominal lymphangioleiomyomatosis in a man with Klinefelter syndrome: the first reported case. Annals of Diagnostic Pathology, 2005, 9, 96-100.	0.6	9
59	Urethral Corpus Spongiosum Amyloidosis Presenting with Urethrorrhagia During Erection. Journal of Sexual Medicine, 2009, 6, 2915-2917.	0.3	9
60	Prognostic Factors for Anastomotic Urinary Leakage Following Retropubic Radical Prostatectomy and Correlation With Voiding Outcomes. Medicine (United States), 2016, 95, e3475.	0.4	9
61	Unusual Case Report of Thrombotic Microangiopathy of the Small Bowel Following Liver Transplantation, a Possible Immunosuppressant-Induced Disease with Histological and Ultrastructural Findings. Scientific World Journal, The, 2009, 9, 1031-1034.	0.8	9
62	Role of androgen receptor expression in non-muscle-invasive bladder cancer: a systematic review and meta-analysis. Histology and Histopathology, 2020, 35, 423-432.	0.5	9
63	What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 2: Clinic–Pathologic Correlations. Cells, 2021, 10, 3165.	1.8	9
64	Evolving concepts and use of immunohistochemical biomarkers in flat non-neoplastic urothelial lesions: WHO 2016 classification update with diagnostic algorithm. Biomarkers, 2018, 23, 305-314.	0.9	8
65	Diagnostic and prognostic roles of CK20 in the pathology of urothelial lesions. A systematic review. Pathology Research and Practice, 2019, 215, 152413.	1.0	8
66	Does Multiparametric Magnetic Resonance of Prostate Outperform Risk Calculators in Predicting Prostate Cancer in Biopsy NaÃ ⁻ ve Patients?. Frontiers in Oncology, 2020, 10, 603384.	1.3	8
67	Intraoperative Digital Analysis of Ablation Margins (DAAM) by Fluorescent Confocal Microscopy to Improve Partial Prostate Gland Cryoablation Outcomes. Cancers, 2021, 13, 4382.	1.7	8
68	The classification of neuroendocrine neoplasms of the lung and digestive system according to WHO, 5th edition: similarities, differences, challenges, and unmet needs. Panminerva Medica, 2022, 64, .	0.2	7
69	Are We Ready to Implement Molecular Subtyping of Bladder Cancer in Clinical Practice? Part 1: General Issues and Marker Expression. International Journal of Molecular Sciences, 2022, 23, 7819.	1.8	7
70	Gliomatosis cerebri type II: two case reports. Journal of Medical Case Reports, 2009, 3, .	0.4	6
71	HER2 assessment by silver <i>in situ</i> hybridization: where are we now?. Expert Review of Molecular Diagnostics, 2015, 15, 385-398.	1.5	6
72	Typing the atypical: Diagnostic issues and predictive markers in suspicious prostate lesions. Critical Reviews in Clinical Laboratory Sciences, 2017, 54, 309-325.	2.7	6

#	Article	IF	CITATIONS
73	Asymptomatic solitary bladder plasmocytoma. Medicine (United States), 2017, 96, e9347.	0.4	6
74	Assessing treatment response after intravesical bacillus Calmette–Guerin induction cycle: are routine bladder biopsies necessary?. World Journal of Urology, 2021, 39, 3815-3821.	1.2	6
75	What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 5: Epigenetic Regulation of PD-L1. International Journal of Molecular Sciences, 2021, 22, 12314.	1.8	6
76	What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 7: PD-L1 Expression in Liquid Biopsy. Journal of Personalized Medicine, 2021, 11, 1312.	1.1	6
77	Pilonidal Cyst of the Penis Mimicking Carcinoma. Case Reports in Urology, 2013, 2013, 1-2.	0.1	5
78	The complex relationship between upper urinary tract and bladder cancer: clinical and predictive issues. Translational Andrology and Urology, 2018, 7, S248-S251.	0.6	5
79	Anaplastic Kaposi's Sarcoma of the Adrenal in an HIV-negative Patient With Literature Review. Advances in Anatomic Pathology, 2019, 26, 133-149.	2.4	5
80	Impact of time to second transurethral resection on oncological outcomes of patients with high-grade T1 bladder cancer treated with intravesical Bacillus Calmette–Guerin. World Journal of Urology, 2020, 38, 3161-3167.	1.2	5
81	Detection of novel Human papilloma virus type 82 in laryngeal cancer: case report. Auris Nasus Larynx, 2010, 37, 648-650.	0.5	4
82	Multiple Skeletal Muscle Metastases from Colon Carcinoma Preceded by Paraneoplastic Dermatomyositis. Case Reports in Medicine, 2013, 2013, 1-4.	0.3	4
83	On a Rare Cutaneous Metastasis from a Sacrococcygeal Chordoma. Case Reports in Pathology, 2017, 2017, 1-4.	0.2	4
84	Daily tadalafil for the chronic phase of stuttering priapism: a case report. BMC Urology, 2018, 18, 54.	0.6	4
85	HHV8-Positive Castleman Disease and In Situ Mantle Cell Neoplasia within Dermatopathic Lymphadenitis, in Longstanding Psoriasis. Diagnostics, 2021, 11, 1150.	1.3	4
86	Methods to identify molecular expression of mTOR pathway: a rationale approach to stratify patients affected by clear cell renal cell carcinoma for more likely response to mTOR inhibitors. American Journal of Cancer Research, 2014, 4, 907-15.	1.4	4
87	A Case of Ovarian Psammocarcinoma Associated with Endometrioid Cysts: A Morphological and Immunohistochemical Study. Tumori, 2009, 95, 112-114.	0.6	3
88	Spontaneous Cutaneous Cholesterol Crystal Embolism With Focal Clinical Symptomatology: Report of a Case in an Unusual Location With Secondary Histological Changes Reminiscent of Atypical Decubital Fibroplasia. American Journal of Dermatopathology, 2011, 33, 726-728.	0.3	3
89	Epidermoid cyst of the coronal sulcus mimicking penile cancer: a case report. Journal of Medical Case Reports, 2014, 8, 179.	0.4	3
90	Voluminous Omental Inflammatory Myofibroblastic Tumor in an Elderly Man: A Case Report and Literature Review. Case Reports in Surgery, 2015, 2015, 1-5.	0.2	3

#	Article	IF	CITATIONS
91	Distinctive morphological and molecular features of urothelial carcinoma with an inverted growth pattern. Journal of Pathology and Translational Medicine, 2021, 55, 239-246.	0.4	3
92	Mitofusin-2 Down-Regulation Predicts Progression of Non-Muscle Invasive Bladder Cancer. Diagnostics, 2021, 11, 1500.	1.3	3
93	Can Inspection of the Mouth Help Clinicians Diagnose Crohn's Disease? A Review. Oral Health & Preventive Dentistry, 2017, 15, 223-227.	0.3	3
94	Cutaneous Localization of Classic Hodgkin Lymphoma Associated with Mycosis Fungoides: Report of a Rare Event and Review of the Literature. Life, 2021, 11, 1069.	1.1	3
95	EBV-Driven Lymphoproliferative Disorders and Lymphomas of the Gastrointestinal Tract: A Spectrum of Entities with a Common Denominator (Part 3). Cancers, 2021, 13, 6021.	1.7	3
96	One-Day Prostate Cancer Diagnosis: Biparametric Magnetic Resonance Imaging and Digital Pathology by Fluorescence Confocal Microscopy. Diagnostics, 2022, 12, 277.	1.3	3
97	Primary Diffuse Large B-Cell Lymphoma of the Urinary Bladder: Update on a Rare Disease and Potential Diagnostic Pitfalls. Current Oncology, 2022, 29, 956-968.	0.9	3
98	A case of ovarian psammocarcinoma associated with endometrioid cysts: a morphological and immunohistochemical study. Tumori, 2009, 95, 112-4.	0.6	3
99	Are We Ready to Implement Molecular Subtyping of Bladder Cancer in Clinical Practice? Part 2: Subtypes and Divergent Differentiation. International Journal of Molecular Sciences, 2022, 23, 7844.	1.8	3
100	Simultaneous radical nephroureterectomy and transurethral distal ureter balloon occlusion and detachment. World Journal of Surgical Oncology, 2014, 12, 345.	0.8	2
101	Are Two Meshes Better than One in Sacrocolpopexy for Pelvic Organ Prolapse? Comparison of Single Anterior versus Anterior and Posterior Vaginal Mesh Procedures. Urologia Internationalis, 2021, , 1-9.	0.6	2
102	Prostate cancer biomarkers: a practical review based on different clinical scenarios. Critical Reviews in Clinical Laboratory Sciences, 2022, 59, 297-308.	2.7	2
103	Are We Doing Our Best to Prevent the (Unexpected) Disappointing Side Effects of an Otherwise Successful Cancer Treatment?. Journal of Andrology, 2012, 33, 894-895.	2.0	1
104	Pathological diagnosis of Coronavirus-related nephropathy: insight from postmortem studies. Critical Reviews in Clinical Laboratory Sciences, 2021, 58, 563-575.	2.7	1
105	Long-Term Results of Radical Surgery and Adjuvant Radiotherapy in a Case of Primary Malignant Fibrous Histiocytoma of the Kidney. The Open Urology & Nephrology Journal, 2014, 7, 1-3.	0.2	1
106	Cutaneous Involvement in Diseases with Plasma Cell Differentiation: Diagnostic Approach. Current Oncology, 2022, 29, 3026-3043.	0.9	1
107	Optical coherence tomography imaging in complicated acute myocardial infarction treated with primary angioplasty and AngioJet. Journal of Cardiovascular Medicine, 2009, 10, 581-584.	0.6	0
108	Bioptic prostatic inflammation correlates with false positive rates of multiparametric magnetic resonance imaging in detecting clinically significant prostate cancer. Central European Journal of Urology, 2021, 74, 308-314.	0.2	0